Carboplatin News and Research

RSS
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Drug sensitivity of hepatocellular cancer cells may provide new insights on tumor biology

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Drug synthesized from Kentucky-grown plant shows promise in treating ovarian cancer

Drug synthesized from Kentucky-grown plant shows promise in treating ovarian cancer

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

First-ever phase 3 advanced anal cancer trial opens for patient enrollment

First-ever phase 3 advanced anal cancer trial opens for patient enrollment

New model can predict the risk of adverse side effects of cancer treatment

New model can predict the risk of adverse side effects of cancer treatment

Combination therapy improves survival rates for women with aggressive endometrial cancer

Combination therapy improves survival rates for women with aggressive endometrial cancer

International trial shows better option for treating people with inoperable anal cancer

International trial shows better option for treating people with inoperable anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Drug improves effectiveness of chemotherapy in ovarian cancer patients

Drug improves effectiveness of chemotherapy in ovarian cancer patients

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

NCCN ORP plans to support phase II randomized trial for lung cancer patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

Version of an antibiotic drug extends survival in mice with lethal pediatric brain tumors

Version of an antibiotic drug extends survival in mice with lethal pediatric brain tumors

Study links FAK protein to chemotherapy resistance in ovarian cancer

Study links FAK protein to chemotherapy resistance in ovarian cancer